On the other hand, focusing only on small-molecule inhibitor studies would have clearly indicated the need for further studies on the influence of PDGFRβ in CRC and in the continued use of this therapy option, not knowing that the observed effects are due to the side inhibition of additional kinases. The gene discussed is PDGFRB; the disease is colorectal carcinoma.